Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways

VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Cardiovascular …, 2021 - Springer
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …
被引用次数：28 相关文章
[PDF] academia.edu

[PDF][PDF] Empagliflozin Significantly Prevents the Doxorubicin‑induced Acute Cardiotoxicity via Non‑antioxidant Pathways

VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh, S Müftüoğlu… - academia.edu
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways

V Baris, A DİNÇSOY, E GEDİKLİ, S ZIRH… - CARDIOVASCULAR …, 2021 - avesis.ebyu.edu.tr
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways

V Baris, A DİNÇSOY, E GEDİKLİ… - …, 2021 - avesis.hacettepe.edu.tr
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways

VÖ Barış, AB Dinçsoy, E Gedikli… - Cardiovascular …, 2021 - pubmed.ncbi.nlm.nih.gov
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.

VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Cardiovascular …, 2021 - europepmc.org
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways

BV Özgür, DA Berk, G Esra, Z Selim… - Cardiovascular …, 2021 - search.proquest.com
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways

VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Cardiovascular …, 2021 - hero.epa.gov
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways.

VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Cardiovascular …, 2021 - search.ebscohost.com
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …

Empagliflozin Significantly Prevents the Doxorubicin-induced Acute Cardiotoxicity via Non-antioxidant Pathways

V Baris, A DİNÇSOY, E GEDİKLİ… - …, 2021 - avesis.hacettepe.edu.tr
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …